Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats

Hypertension Research

Volumn 32, Issue 7, 2009, Pages 604-610

  Kawai, Makoto ^a   Hongo, Kenichi ^a   Komukai, Kimiaki ^a   Morimoto, Satoshi ^a   Nagai, Makoto ^a   Seki, Shingo ^a   Taniguchi, Ikuo ^a   Mochizuki, Seibu ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; COLLAGEN; TELMISARTAN;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; LOW DRUG DOSE; MUSCLE CELL; NONHUMAN; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD VESSELS; CARDIOMEGALY; CELL SIZE; CORONARY VESSELS; FIBROSIS; HEART DISEASES; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR;

EID: 67650520177     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.61     Document Type: Article

References (29)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
2. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002; 34 1435-1442.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
4. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study II ELITE. Lancet 2000; 355: 1582-1587.
5. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848-856.
6. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
7. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens Suppl 1996; 14: S95-S103.
8. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K, Yazaki Y. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97: 1952-1959.
9. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
10. Nagai M, Horikoshi K, Izumi T, Seki S, Taniguchi M, Taniguchi I, Mochizuki S. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004; 18: 353-362.
11. Obayashi M, Yano M, Kohno M, Kobayashi S, Tanigawa T, Hironaka K, Ryouke T, Matsuzaki M. Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997; 273: H1824-H1831.
12. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634-638.
13. Tanaka Y, Nagai M, Date T, Okada T, Abe Y, Seki S, Taniguchi M, Taniguchi I, Mochizuki S. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004; 27: 865-875.
14. Ito N, Isoyama S, Takahashi T, Takishima T. Coronary dilator reserve and morphological changes after relief of pressure-overload in rats. J Mol Cell Cardiol 1993; 25: 3-14.
15. O'Sullivan JB, Black MJ, Bertram JF, Bobik A. Cardiovascular hypertrophy in onekidney, one clip renal hypertensive rats: A role for angiotensin II? J Hypertens 1994; 12: 1163-1170.
16. Matsubara LS, Matsubara BB, Okoshi MP, Franco M, Cicogna AC. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol 1997; 75: 1328-1334.
17. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576-581.
18. Liang B, Leenen FH. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J Cardiovasc Pharmacol 2008; 51: 457-466.
19. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2001; 2: 117-122.
20. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006; 72: 184-190.
21. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26: 971-978.
22. Tanabe A, Naruse M, Hara Y, Sato A, Tsuchiya K, Nishikawa T, Imaki T, Takano K. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 2004; 22: 1017-1023.
23. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 1999; 31: 1175-1184.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
25. Okada T, Nagai M, Taniguchi I, Kuno M, Imamoto S, Seki S, Taniguchi M, Mochizuki S. Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats. Int Heart J 2006; 47: 783-793.
26. Sasamura H, Suzuki H, Kato R, Saruta T. Effects of angiotensin II, ACTH, and KCl on the adrenal renin-angiotensin system in the rat. Acta Endocrinol (Copenh) 1990; 122: 369-373.
27. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
28. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
29. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.